Lee, Bianca J.
Boyer, Jacob A.
Burnett, G. Leslie http://orcid.org/0000-0003-2514-9373
Thottumkara, Arun P.
Tibrewal, Nidhi
Wilson, Stacy L.
Hsieh, Tientien
Marquez, Abby
Lorenzana, Edward G.
Evans, James W.
Hulea, Laura http://orcid.org/0000-0001-7585-7760
Kiss, Gert
Liu, Hui
Lee, Dong
Larsson, Ola http://orcid.org/0000-0003-1412-1308
McLaughlan, Shannon
Topisirovic, Ivan
Wang, Zhengping
Wang, Zhican
Zhao, Yongyuan
Wildes, David
Aggen, James B.
Singh, Mallika
Gill, Adrian L.
Smith, Jacqueline A. M. http://orcid.org/0000-0001-5028-8725
Rosen, Neal http://orcid.org/0000-0002-8307-654X
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-20-141)
Article History
Received: 22 May 2020
Accepted: 7 May 2021
First Online: 24 June 2021
Change Date: 29 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41589-021-00843-1
Change Date: 6 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41589-021-00905-4
Competing interests
: N.R. reports grants from Revolutionary Medicines and Boehringer Ingelheim; grants and consulting fees from AstraZeneca and Pfizer Array; consulting fees (scientific advisory board) from Ribon Therapeutics, Tarveda Therapeutics, and Chugai Pharmaceuticals; scientific advisory board fees and equity in Beigene and Zai Laboratories; and equity in Kura Oncology and Fortress. I.T. and O.L. have consulted at and are recipients of research grants from Revolution Medicines. B.J.L., G.L.B., A.P.T., N.T., S.L.W., T.H., A.M., E.G.L., J.W.E., G.K., D.L., Zhengping W., Zhican W., Y.Z., D.W., J.B.A., M.S., A.L.G. and J.A.M.S. are current or former employees of Revolution Medicines, Inc. The other authors declare no competing interests.